For people with microscopic polyangiitis, the immune system sometimes attacks the wrong targets. A new look at genetic data from a Chinese group of patients and healthy controls reveals a hidden risk factor. Researchers found that a heavy load of certain genes in a specific pathway made people more likely to develop this condition. This pathway helps control how cells grow and function, and when it is genetically overactive, the body may lose its ability to distinguish between threats and normal tissue. The study also noted that some common genetic patterns were less common in patients, suggesting they might offer some protection. These findings help explain why some individuals are more vulnerable than others, even when their environment looks similar. However, the team warns that these links need to be checked in larger groups before they can guide medical decisions. Understanding these genetic roots is a step toward better screening and personalized care for those at risk.
Genetic burden in PI3K–AKT–mTOR pathway linked to microscopic polyangiitis susceptibility in Chinese cohortGenetic markers linked to higher risk of microscopic polyangiitis in Chinese patients
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider that high genetic burden in the PI3K–AKT–mTOR pathway may increase MPA susceptibility, but validation is needed.
This observational cohort study investigated the association between genetic burden across core genes of the PI3K–AKT–mTOR pathway (PIK3CA, AKT1, and MTOR) and susceptibility to microscopic polyangiitis (MPA) in a Chinese cohort including MPA patients and controls. The primary outcome was susceptibility to MPA, with secondary outcomes including MPO-ANCA positivity and sex-related associations.
The main results showed that high genetic burden was associated with increased susceptibility to MPA, while intermediate burden showed no significant association. Pathway-level genetic burden was also associated with MPO-ANCA positivity. Several common haplotypes spanning PIK3CA, AKT1, and MTOR were less frequent among patients, suggesting protective effects.
No safety or tolerability data were reported for this genetic association study. Key limitations include that associations should be interpreted cautiously and require validation in larger and independent cohorts. The study did not report sample size, follow-up duration, or effect sizes.
Practice relevance is limited by the observational design and lack of absolute numbers or statistical measures. The findings suggest a potential genetic role in MPA pathogenesis but do not establish causality.
What this means for you:
A high genetic burden in a key pathway increases susceptibility to microscopic polyangiitis. More on Microscopic Polyangiitis
ANCA-associated vasculitis associated with higher mortality and cardiovascular events in retrospective cohort analysis
New data links rare blood vessel diseases to higher death and heart risks
This retrospective cohort study analyzed 20,422 patients with granulomatosis with polyangiitis and 5,907 with microscopic polyangiitis using…
People with rare blood vessel diseases face nearly three times the death risk and higher heart attack rates compared to healthy people.
Japanese AAV Cohort Shows MPA Has 67.6% Five-Year Survival; Glucocorticoid Reduction Not Linked to Better Outcomes
For Japanese patients with a rare autoimmune disease, survival remains challenging
A retrospective cohort study of 460 treatment-naïve Japanese patients with AAV found microscopic polyangiitis (MPA) had the poorest prognosi…
Japanese patients with microscopic polyangiitis face a five-year survival rate of 67.6%, as older age and kidney issues raise death risk.
View Original Abstract ↓
The PI3K–AKT–mTOR signaling pathway plays a central role in immune regulation and has been implicated in autoimmune diseases. However, the contribution of genetic variation within key components of this pathway to microscopic polyangiitis (MPA) remains incompletely understood.
We conducted a genetic association study in a Chinese cohort including MPA patients and controls. Four single nucleotide polymorphisms (SNPs) within core genes of the PI3K–AKT–mTOR pathway (PIK3CA, AKT1, and MTOR) were analyzed. A cumulative genetic burden score was constructed by summing the number of risk alleles across loci. Participants were stratified into burden categories based on the distribution in controls. Logistic regression, trend analysis, and sensitivity analyses restricted to hospital-based controls were performed.
A high genetic burden within the PI3K-AKT-mTOR pathway was associated with increased susceptibility to MPA, with a significant linear trend across burden categories, whereas the intermediate burden group showed no significant association, suggesting a threshold-dependent effect. In sex−stratified analyses, associations appeared more evident among females, although a formal test for interaction did not indicate statistical significance. Analyses suggest a potential sex-related trend that warrants further investigation. Sensitivity analyses restricted to hospital-based controls yielded consistent results. Several common haplotypes spanning PIK3CA, AKT1, and MTOR were less frequent among patients, indicating potential protective effects. Pathway-level genetic burden was also associated with MPO-ANCA positivity. Single-variant analyses revealed generally concordant but modest effects.
Genetic variation across selected core components of the PI3K--AKT--mTOR pathway may contribute to susceptibility to MPA. The observed patterns, including potential sex-related differences, should be interpreted cautiously and require validation in larger and independent cohorts. These findings highlight a potential pathway-level genetic architecture underlying MPA susceptibility.
Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Related in Dermatology
FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
FDA approves Skyrizi for adults with moderate to severe ulcerative colitis.
The FDA approved Skyrizi (risankizumab) for moderately to severely active ulcerative colitis in adults. The recommended induction dosage is …
The FDA approved Skyrizi (risankizumab) for adults with moderate to severe ulcerative colitis. It is given as an IV infusion at first, then …
FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
FDA approves Skyrizi for ulcerative colitis, a new treatment option.
The FDA approved Skyrizi (risankizumab) for moderately to severely active ulcerative colitis in adults. The approval adds to existing indica…
The FDA approved Skyrizi (risankizumab) for adults with moderate to severe ulcerative colitis. It is given as an IV infusion at first, then …
FDA Approves Absorica LD (isotretinoin) for Severe Recalcitrant Nodular Acne
FDA approves new acne drug Absorica LD for severe nodular acne.
FDA approved Absorica LD (isotretinoin) for severe recalcitrant nodular acne in non-pregnant patients aged 12 and older. It is reserved for …
The FDA approved Absorica LD (isotretinoin) for severe nodular acne in patients 12 and older. It is for those who have not improved with oth…
FDA Approves Absorica (isotretinoin) for Severe Recalcitrant Nodular Acne
FDA approves new acne drug Absorica for severe cases
The FDA approved Absorica (isotretinoin) for severe recalcitrant nodular acne in non-pregnant patients 12 years and older. It is reserved fo…
The FDA approved Absorica (isotretinoin) for severe nodular acne in patients 12 and older. It is for those who have not improved with other …
From Other Specialties
Myopia prevalence among Malaysian children is estimated between 16% and 25% depending on diagnostic methods
Analysis Shows Myopia Prevalence Among Children in Malaysia
This meta-analysis of 17 studies involving 19,281 Malaysian children found an unadjusted myopia prevalence of 25.0%. Cycloplegic refraction …
A large analysis of Malaysian children shows that the prevalence of myopia likely falls between 16% and 25%.
Nirsevimab and maternal RSVpreF vaccination show approximately 80% effectiveness against RSV-associated hospitalization in children
Nirsevimab and Maternal Vaccination Show Promise for RSV Protection
This meta-analysis of 43 observational studies evaluates nirsevimab and maternal RSVpreF vaccination for preventing RSV-associated hospitali…
New data suggests that nirsevimab and maternal vaccination may significantly reduce hospitalizations caused by the respiratory syncytial vir…
Erythropoietin Dynamics and Neuroimaging Outcomes in Extremely Preterm Infants with Retinopathy
Erythropoietin Levels Linked to Brain Injury in Preterm Infants
This post-hoc analysis explores how erythropoietin levels correlate with MRI findings of brain injury and retinopathy in extremely preterm i…
New data explores how erythropoietin levels and blood transfusions impact brain health and eye risks in extremely preterm infants.
Tailored counseling for breastfeeding among people living with HIV supports individualized care after 2023 guidelines
New Guidelines Shape Breastfeeding Practices for People Living with HIV
This scoping review examines breastfeeding practices and perspectives following the 2023 US national guideline changes for people living wit…
Newer guidelines offer more personalized breastfeeding support for people living with HIV during the peripartum and postpartum periods.